Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329023 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL1844594 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12579136 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12693260 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12696579 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL1844823 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL1844825 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL974023 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| Hydrochloric Acid SCHEMBL2823637 | 0.98 | HSD11B1 (0.39) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL3644747 | 0.87 | HSD11B1 (0.43) | HSD11B1HSD11B2DGAT1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| EP-2364311-B1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-2364311-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010049635-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | BHMT, UGDH, NNMT | HSD11B1 4293/4885HSD11B2 4431/4885DGAT1 1785/4885 |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | HSD11B1 2913/4885HSD11B2 3024/4885DGAT1 1137/4885 |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | HSD11B1 1963/4885HSD11B2 1686/4885DGAT1 3178/4885 |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885HSD11B2 5/4885DGAT1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.